The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis

Journal of the National Cancer Institute

Volumn 94, Issue 18, 2002, Pages 1381-1395

  Bugajska, Urszula ^a   Georgopoulos, Nikolaos T ^a   Southgate, Jennifer ^b   Johnson, Peter W M ^a   Graber, Pierre ^c   Gordon, John ^d   Selby, Peter J ^a   Trejdosiewicz, Ludwik K ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

^d UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD32 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; DNA FRAGMENT; FAS ANTIBODY; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; MESSENGER RNA; PROTEIN P53; TRITIUM; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; ASSAY; CANCER GROWTH; CARCINOGENESIS; CARCINOMA CELL; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; DNA SYNTHESIS; FIBROBLAST; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN MOTIF; SIGNAL TRANSDUCTION; STAINING; STATISTICAL ANALYSIS; TRANSITIONAL CELL CARCINOMA; UROTHELIUM;

EID: 0037130890     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.18.1381     Document Type: Article

References (84)

1. Grewal IS, Flavell RA. The CD40 ligand. At the center of the immune universe? Immunol Res 1997;16:59-70.
2. Van Kooten C, Banchereau J. Functional role of CD40 and its ligand. Int Arch Allergy Immunol 1997;113:393-9.
3. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111-35.
4. Mackey MF, Barth RJ Jr, Noelle RJ. The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J Leukoc Biol 1998;63:418-28.
5. Toes RE, Schoenberger SP, van der Voort EI, Offringa R, Melief CJ. CD40-CD40 ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin Immunol 1998;10:443-8.
6. Biancone L, Cantaluppi V, Camussi G. CD40-CD154 interaction in experimental and human disease. Int J Mol Med 1999;3:343-53.
7. Heath WR, Carbone FR. Cytotoxic T lymphocyte activation by cross-priming. Curr Opin Immunol 1999;11:314-8.
8. Van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67:2-17.
9. Gordon J, Pound JD. Fortifying B cells with CD154: an engaging tale of many hues. Immunology 2000;100:269-80.
10. Gordon J. CD40 and its ligand: central players in B lymphocyte survival, growth, and differentiation. Blood Rev 1995;9:53-6.
11. Van Kooten C, Banchereau J. Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol 1997;9:330-7.
12. Klaus GG, Choi MS, Lam EW, Johnson-Leger C, Cliff J. CD40: a pivotal receptor in the determination of life/death decisions in B lymphocytes. Int Rev Immunol 1997;15:5-31.
13. Lens SM, Tesselaar K, den Drijver BF, van Oers MH, van Lier RA. A dual role for both CD40-ligand and TNF-alpha in controlling human B cell death. J Immunol 1996;156:507-14.
14. Lagresle C, Mondiere P, Bella C, Krammer PH, Defrance T. Concurrent engagement of CD40 and the antigen receptor protects naive and memory human B cells from APO-1/Fas-mediated apoptosis. J Exp Med 1996;183: 1377-88.
15. Grell M, Zimmermann G, Gottfried E, Chen CM, Grunwald U, Huang DC, et al. Induction of cell death by tumor necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J 1999;18:3034-43.
16. Afford SC, Randhawa S, Eliopoulos AG, Hubscher SG, Young LS, Adams DH. CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface Fas ligand expression and amplifies Fas-mediated hepatocyte death during allograft rejection. J Exp Med 1999;189:441-6.
17. Eliopoulos AG, Davies C, Knox PG, Gallagher NJ, Afford SC, Adams DH, et al. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol 2000;20:5503-15.
18. Afford SC, Ahmed-Choudhury J, Randhawa S, Russell C, Youster J, Crosby HA, et al. CD40 activation-induced, Fas-dependent apoptosis and NF-kappaB/AP-1 signaling in human intrahepatic biliary epithelial cells. FASEB J 2001;15:2345-54.
19. Galy AH, Spits H. CD40 is functionally expressed on human thymic epithelial cells. J Immunol 1992;149:775-82.
20. Denfeld RW, Hollenbaugh D, Fehrenbach A, Weiss JM, von Leoprechting A, Mai B, et al. CD40 is functionally expressed on human keratinocytes. Eur J Immunol 1996;26:2329-34.
21. Gaspari AA, Sempowski GD, Chess P, Gish J, Phipps RP. Human epidermal keratinocytes are induced to secrete interleukin-6 and costimulate T lymphocyte proliferation by a CD40-dependent mechanism. Eur J Immunol 1996;26:1371-7.
22. Boonstra JG, van der Woude FJ, Wever PC, Laterveer JC, Daha MR, Van Kooten C. Expression and function of Fas (CD95) on human renal tubular epithelial cells. J Am Soc Nephrol 1997;8:1517-24.
23. Peguet-Navarro J, Dalbiez-Gauthier C, Moulon C, Berthier O, Reano A, Gaucherand M, et al. CD40 ligation of human keratinocytes inhibits their proliferation and induces their differentiation. J Immunol 1997;158: 144-52.
24. Van Kooten C, Gerritsma JS, Paape ME, Van Es LA, Banchereau J, Daha MR. Possible role for CD40-CD40L in the regulation of interstitial infiltration in the kidney. Kidney Int 1997;51:711-21.
25. Van Kooten C, van der Linde X, Woltman AM, Van Es LA, Daha MR. Synergistic effect of interleukin-1 and CD40L on the activation of human renal tubular epithelial cells. Kidney Int 1999;56:41-51.
26. Altenburg A, Baldus SE, Smola H, Pfister H, Hess S. CD40 ligand-CD40 interaction induces chemokines in cervical carcinoma cells in synergism with IFN-gamma. J Immunol 1999;162:4140-7.
27. Yellin MJ, Winikoff S, Fortune SM, Baum D, Crow MK, Lederman S, et al. Ligation of CD40 on fibroblasts induces CD54 (ICAM-1) and CD106 (VCAM-1) up-regulation and IL-6 production and proliferation. J Leukoc Biol 1995;58:209-16.
28. Rissoan MC, Van Kooten C, Chomarat P, Galibert L, Durand I, Thivolet-Bejui F, et al. The functional CD40 antigen of fibroblasts may contribute to the proliferation of rheumatoid synovium. Clin Exp Immunol 1996;106: 481-90.
29. Eliopoulos AG, Dawson CW, Mosialos G, Floettmann JE, Rowe M, Armitage RJ, et al. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 1996;13:2243-54.
30. Eliopoulos AG, Stack M, Dawson CW, Kaye KM, Hodgkin L, Sihota S, et al. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors. Oncogene 1997;14:2899-916.
31. Wingett DG, Vestal RE, Forcier K, Hadjokas N, Nielson CP. CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis. Breast Cancer Res Treat 1998;50:27-36.
32. Posner MR, Cavacini LA, Upton MP, Tillman KC, Gornstein ER, Norris CM Jr. Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines. Clin Cancer Res 1999;5:2261-70.
33. Hirano A, Longo DL, Taub DD, Ferris DK, Young LS, Eliopoulos AG, et al. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 1999;93:2999-3007.
34. Tong AW, Papayoti MH, Armstrong DT, Ordonez G, Lawson JM, Stone MJ. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res 2001;7:691-703.
35. Hess S, Engelmann H. A novel function of CD40: induction of cell death in transformed cells. J Exp Med 1996;183:159-67.
36. Hayward AR, Levy J, Facchetti F, Notarangelo L, Ochs HD, Etzioni A, et al. Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J Immunol 1997; 158:977-83.
37. Cosyns M, Tsirkin S, Jones M, Flavell R, Kikutani H, Hayward AR. Requirement of CD40-CD40 ligand interaction for elimination of Cryptosporidium parvum from mice. Infect Immun 1998;66:603-7.
38. Young LS, Eliopoulos AG, Gallagher NJ, Dawson CW. CD40 and epithelial cells: across the great divide. Immunol Today 1998;19:502-6.
39. Ghamande S, Hylander BL, Oflazoglu E, Lele S, Fanslow W, Repasky EA. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res 2001;61: 7556-62.
40. Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, et al. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997;57:1758-68.
41. Jakobson E, Jonsson G, Bjorck P, Paulie S. Stimulation of CD40 in human bladder carcinoma cells inhibits anti-Fas/APO-1 (CD95)-induced apoptosis. Int J Cancer 1998;77:849-53.
42. Laytragoon-Lewin N. Programmed cell death: the influence of CD40, CD95 (Fas or Apo-I) and their ligands. Med Oncol 1998;15:15-9.
43. Sbih-Lammali F, Clausse B, Ardila-Osorio H, Guerry R, Talbot M, Havouis S, et al. Control of apoptosis in Epstein Barr virus-positive nasopharyngeal carcinoma cells: opposite effects of CD95 and CD40 stimulation. Cancer Res 1999;59:924-30.
44. Sugimoto K, Shiraki K, Ito T, Fujikawa K, Takase K, Tameda Y, et al. Expression of functional CD40 in human hepatocellular carcinoma. Hepatology 1999;30:920-6.
45. Southgate J, Masters JR, Trejdosiewicz LK. Culture of human urothelium. In: Freshney RI, Freshney MG, editors. Culture of epithelial cells. 2nd ed. New York (NY): J. Wiley & Sons, Inc.; 2002. p. 381-400.
46. Southgate J, Hutton KA, Thomas DF, Trejdosiewicz LK. Normal human urothelial cells in vitro: proliferation and induction of stratification. Lab Invest 1994;71:583-94.
47. Scriven SD, Booth C, Thomas DF, Trejdosiewicz LK, Southgate J. Reconstitution of human urothelium from monolayer cultures. J Urol 1997;158: 1147-52.
48. Reznikoff CA, Belair CD, Yeager TR, Savelieva E, Blelloch RH, Puthenveettil JA, et al. A molecular genetic model of human bladder cancer pathogenesis. Semin Oncol 1996;23:571-84.
49. Knowles MA. The genetics of transitional cell carcinoma: progress and potential clinical application. BJU Int 1999;84:412-27.
50. Diggle CP, Pitt E, Roberts P, Trejdosiewicz LK, Southgate J. n-3 and n-6 polyunsaturated fatty acids induce cytostasis in human urothelial cells independent of p53 gene function. J Lipid Res 2000;41:1509-15.
51. Diggle CP, Pitt E, Harnden P, Trejdosiewicz LK, Southgate J. Role of p53 in the responses of human urothelial cells to genotoxic damage. Int J Cancer 2001;93:199-203.
52. Masters JR, Hepburn PJ, Walker L, Highman WJ, Trejdosiewicz LK, Povey S, et al. Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines. Cancer Res 1986; 46:3630-6.
53. Challa A, Pound JD, Armitage RJ, Gordon J. Epitope-dependent synergism and antagonism between CD40 antibodies and soluble CD40 ligand for the regulation of CD23 expression and IgE synthesis in human B cells. Allergy 1999;54:576-83.
54. Pound JD, Challa A, Holder MJ, Armitage RJ, Dower SK, Fanslow WC, et al. Minimal cross-linking and epitope requirements for CD40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells. Int Immunol 1999;11:11-20.
55. Baccam M, Bishop GA. Membrane-bound CD154, but not CD40-specific antibody, mediates NF-kappaB-independent IL-6 production in B cells. Eur J Immunol 1999;29:3855-66.
56. McCloskey N, Pound JD, Holder MJ, Williams JM, Roberts LM, Lord JM, et al. The extrafollicular-to-follicular transition of human B lymphocytes: induction of functional globotriaosylceramide (CD77) on high threshold occupancy of CD40. Eur J Immunol 1999;29:3236-44.
57. Trejdosiewicz LK, Southgate J, Donald JA, Masters JR, Hepburn PJ, Hodges GM. Monoclonal antibodies to human urothelial cell lines and hybrids: production and characterization. J Urol 1985;133:533-8.
58. Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC. CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 1995; 85:1903-12.
59. Gagro A, Gordon J. The interplay between T helper subset cytokines and IL-12 in directing human B lymphocyte differentiation. Eur J Immunol 1999;29:3369-79.
60. Gagro A, McCloskey N, Challa A, Holder M, Grafton G, Pound JD, et al. CD5-positive and CD5-negative human B cells converge to an indistinguishable population on signalling through B-cell receptors and CD40. Immunology 2000;101:201-9.
61. Mazzei GJ, Edgerton MD, Losberger C, Lecoanet-Henchoz S, Graber P, Durandy A, et al. Recombinant soluble trimeric CD40 ligand is biologically active. J Biol Chem 1995;270:7025-8.
62. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075-82.
63. Southgate J, Kennedy W, Hutton KA, Trejdosiewicz LK. Expression and in vitro regulation of integrins by normal human urothelial cells. Cell Adhes Commun 1995;3:231-42.
64. Cruickshank SM, Southgate J, Selby PJ, Trejdosiewicz LK. Expression and cytokine regulation of immune recognition elements by normal human biliary epithelial and established liver cell lines in vitro. J Hepatol 1998; 29:550-8.
65. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A 1990;87:3127-31.
66. Lobban ED, Smith BA, Hall GD, Harnden P, Roberts P, Selby PJ, et al. Uroplakin gene expression by normal and neoplastic human urothelium. Am J Pathol 1998;153:1957-67.
67. Southgate J, Pitt E, Trejdosiewicz LK. The effects of dietary fatty acids on the proliferation of normal human urothelial cells in vitro. Br J Cancer 1996;74:728-34.
68. Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T, Traganos F. Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry 1997;27:1-20.
69. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994;84:1415-20.
70. Sillett HK, Cruickshank SM, Southgate J, Trejdosiewicz LK. Transforming growth factor-beta promotes "death by neglect" in post-activated human T cells. Immunology 2001;102:310-6.
71. Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell death. J Immunol Methods 1991;145:185-92.
72. Southgate J, Trejdosiewicz LK. Immunolabelling of cells and tissues: approaches and pitfalls. Hum Reprod 1997;12 Suppl:65-75.
73. Hutchins D, Steel CM. Regulation of ICAM-1 (CD54) expression in human breast cancer cell lines by interleukin 6 and fibroblast-derived factors. Int J Cancer 1994;58:80-4.
74. Baichwal VR, Baeuerle PA. Apoptosis: activate NF-kappaB or die? Curr Biol 1997;7:R94-6.
75. Baker SJ, Reddy EP. Modulation of life and death by the TNF receptor superfamily. Oncogene 1998;17:3261-70.
76. Booth C, Harnden P, Trejdosiewicz LK, Scriven S, Selby PJ, Southgate J. Stromal and vascular invasion in an human in vitro bladder cancer model. Lab Invest 1997;76:843-57.
77. Gruss HJ, Herrmann F, Gattei V, Gloghini A, Pinto A, Carbone A. CD40/CD40 ligand interactions in normal, reactive and malignant lymphohematopoietic tissues. Leuk Lymphoma. 1997;24:393-422.
78. Costello RT, Gastaut JA, Olive D. What is the real role of CD40 in cancer immunotherapy? Immunol Today 1999;20:488-93.
79. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 1997;186:2045-50.
80. Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet 1999;33:29-55.
81. Arch RH, Gedrich RW, Thompson CB. Tumor necrosis factor receptor-associated factors (TRAFs) - a family of adapter proteins that regulates life and death. Genes Dev 1998;12:2821-30.
82. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME. Apoptosis signaling by death receptors. Eur J Biochem 1998;254:439-59.
83. Glaser T, Wagenknecht B, Weller M. Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells. Oncogene 2001;20:4757-67.
84. Cooke PW, James ND, Ganesan R, Wallace M, Burton A, Young LS. CD40 expression in bladder cancer. J Pathol 1999;188:38-43.